Data / Drug companies / Guanfacine
Guanfacine: 33 companies and 101 products in the FDA NDC directory
Guanfacine is listed in the FDA National Drug Code Directory by 33 companies, with 101 products in commercial distribution. 97 of the products (96.0%) are marketed under an abbreviated new drug application (ANDA), the generic route. The most common dosage forms are tablet, extended release; tablet, and the newest product started marketing on October 2, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Companies listing it
- 33
- Products
- 101
- Generic (ANDA) products
- 97 (96.0%)
- Application numbers
- 16
- Routes
- Oral
- Brand names
- Intuniv
- openFDA record search
- api.fda.gov
Companies that list guanfacine
Ranked by number of products. Finished drugs in commercial distribution.
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| Remedyrepack Inc. | 7 | tablet, extended release; tablet | Generic drugs (ANDA) | June 2, 2026 |
| Advagen Pharma Ltd | 6 | tablet, extended release; tablet | Generic drugs (ANDA) | April 15, 2025 |
| Upsher-Smith Laboratories, LLC | 6 | tablet, extended release; tablet | Generic drugs (ANDA) | September 1, 2022 |
| Bryant Ranch Prepack | 5 | tablet, extended release | Generic drugs (ANDA) | August 8, 2023 |
| A-S Medication Solutions | 4 | tablet, extended release; tablet | Generic drugs (ANDA) | August 8, 2023 |
| Actavis Pharma, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | December 1, 2014 |
| Alembic Pharmaceuticals Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | August 8, 2023 |
| Alembic Pharmaceuticals Limited | 4 | tablet, extended release | Generic drugs (ANDA) | August 8, 2023 |
| Apotex Corp. | 4 | tablet, extended release | Generic drugs (ANDA) | October 3, 2018 |
| Fosun Pharma USA Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | April 3, 2026 |
| Golden State Medical Supply, Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | August 7, 2023 |
| NorthStar Rx LLC | 4 | tablet, extended release | Generic drugs (ANDA) | September 17, 2021 |
| Proficient Rx LP | 4 | tablet, extended release | Generic drugs (ANDA) | July 7, 2017 |
| Slate Run Pharmaceuticals, LLC | 4 | tablet, extended release | Generic drugs (ANDA) | August 1, 2022 |
| Takeda Pharmaceuticals America, Inc. | 4 | tablet, extended release | New drug applications (NDA) | September 2, 2009 |
| Unichem Pharmaceuticals (USA), Inc. | 4 | tablet, extended release | Generic drugs (ANDA) | November 19, 2024 |
| Bryant Ranch Prepack | 3 | tablet, extended release | Generic drugs (ANDA) | August 17, 2018 |
| Golden State Medical Supply, Inc. | 3 | tablet, extended release | Generic drugs (ANDA) | June 2, 2015 |
| Actavis Pharma, Inc. | 2 | tablet | Generic drugs (ANDA) | October 17, 1995 |
| Ajanta Pharma USA Inc. | 2 | tablet | Generic drugs (ANDA) | April 27, 2023 |
| Amneal Pharmaceuticals LLC | 2 | tablet | Generic drugs (ANDA) | November 25, 1998 |
| Amneal Pharmaceuticals of New York LLC | 2 | tablet | Generic drugs (ANDA) | April 15, 2022 |
| Bryant Ranch Prepack | 2 | tablet, extended release | Generic drugs (ANDA) | August 17, 2018 |
| Chartwell RX, LLC | 2 | tablet | Generic drugs (ANDA) | September 1, 2022 |
| Coupler LLC | 2 | tablet | Generic drugs (ANDA) | January 28, 2026 |
| Epic Pharma, LLC | 2 | tablet | Generic drugs (ANDA) | December 2, 2013 |
| AvPAK | 1 | tablet | Generic drugs (ANDA) | June 7, 2017 |
| Direct_Rx | 1 | tablet, extended release | Generic drugs (ANDA) | October 2, 2026 |
| Major Pharmaceuticals | 1 | tablet | Generic drugs (ANDA) | December 2, 2013 |
| Precision Dose, Inc. | 1 | tablet | Generic drugs (ANDA) | January 31, 2023 |
| Proficient Rx LP | 1 | tablet | Generic drugs (ANDA) | December 2, 2013 |
| Puracap Laboratories LLC DBA Blu Pharmaceuticals | 1 | tablet | Generic drugs (ANDA) | November 14, 2016 |
| St. Mary's Medical Park Pharmacy | 1 | tablet, extended release | Generic drugs (ANDA) | May 19, 2025 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet, extended release | 75 | 74.3% |
| Tablet | 26 | 25.7% |
Marketing categories
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 97 | 96% |
| New drug applications (NDA) | 4 | 4% |
Pharmacologic classes
| Class | Products |
|---|---|
| Central alpha-2 Adrenergic Agonist | 101 |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.